Blechman Foundation-funded study published in Science Translational Medicine

In June 2016, researchers at the University of Pittsburgh School of Medicine announced a major breakthrough from a study, funded in part by the Blechman Foundation, that explains why the Parkinson’s-related protein alpha-synuclein is toxic to neurons in the brain. The findings offer promise to identify new therapies that could slow or stop the progression of the degenerative illness, and were published in Science Translational Medicine (“a-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease”). 
You can read the full text of the journal article below and the abstract here. For more information, please see the official press release and additional coverage from NPR and Altmetric. 

page 1page 2page 3page 4page 5page 6page 7page 8page 9page 10page 11page 12page 13page 14page 15

Copyright © 2017 Blechman Foundation Inc. All rights reserved. 501(c)(3) Certified.